SKINKANDY LIMITED (SK1)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SK1 - SKINKANDY LIMITED

FNArena Sector : Health & Nutrition
Year End: June
GICS Industry Group : Consumer Services
Debt/EBITDA: 1.09
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.65

07 Jul
2026

0.060

OPEN

$2.55

2.32%

HIGH

$2.67

62,047

LOW

$2.48

TARGET
$2.80 5.7% upside
OTHER COMPANIES IN THE SAME SECTOR
CLV . EBO . EXL . MCP . SIG .
FNARENA'S MARKET CONSENSUS FORECASTS
SK1: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 7.3 7.7 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx 33.3% 5.8% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 34.8 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202320242025
EPS Basic xxxxxx7.3
DPS All xxxxxx0.0
Sales/Revenue xxxxxx71.8 M
Book Value Per Share xxxxxx27.3
Net Operating Cash Flow xxxxxx12.1 M
Net Profit Margin xxxxxx11.33 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202320242025
Return on Capital Employed xxxxxx28.77 %
Return on Invested Capital xxxxxx19.78 %
Return on Assets xxxxxx14.50 %
Return on Equity xxxxxx28.77 %
Return on Total Capital xxxxxx26.04 %
Free Cash Flow ex dividends xxxxxx4.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202320242025
Short-Term Debt xxxxxx7 M
Long Term Debt xxxxxx15 M
Total Debt xxxxxx22 M
Goodwill - Gross xxxxxx9 M
Cash & Equivalents - Generic xxxxxx9 M
Price To Book Value xxxxxx-

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202320242025
Capex xxxxxx3.9 M
Capex % of Sales xxxxxx5.47 %
Cost of Goods Sold xxxxxx46 M
Selling, General & Admin. Exp & Other xxxxxx14 M
Research & Development xxxxxx-
Investments - Total xxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

09/06/2026

1

Initiation of coverage with Buy

$2.90

9.43%

Morgans initiates coverage on specialty piercing retailer SkinKandy with a Buy rating and target of $2.90.

SkinKandy operates 107 piercing-focused retail stores across A&NZ, with the analyst highlighting a service-led, vertically integrated model supported by strong store economics and high barriers to entry.

The broker sees multiple growth drivers, including store maturation, improving profitability and a self-funded rollout of 15-20 stores annually. International expansion into the US, UK and South Africa from 2027 is also seen as providing additional upside potential.

Morgans forecasts earnings per share growth of 33% annually between FY25 and FY28, underpinned by revenue growth, operating leverage and margin expansion.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of 7.70 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of 10.40 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

SK1 STOCK CHART

FNArena News on SK1

No Records

Latest Health & Nutrition News

1
The Defensive Proposition Of Sigma Healthcare

Mar 30 2026 - Australia
2
Sigma Healthcare’s Four Pillars Of Growth

Aug 29 2025 - Australia
3
Sigma Healthcare: Synergies, Margins In Focus

Jun 19 2025 - Australia
4
Sigma Healthcare Promises Higher Margins

Oct 03 2023 - Small Caps
5
Sigma’s Win Not Neccessarily Ebos’ Loss

Jun 14 2023 - Small Caps
6
Sigma Healthcare: Brokers Wary

Mar 31 2022 - Australia
7
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
8
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
9
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps
10
Nine Ignored Companies Now Worth A Look

Sep 23 2020 - FYI